curasan AG: Profits warning for 2010

Oct. 4, 2010 - PRLog -- Kleinostheim, Germany – curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8) expects to make a considerable profit instead of the two million euro loss announced for the financial year 2010.

The reason for this is the contract agreement that has just been concluded for the sale of the oncological product Mitem® to the Speciality European Pharma Ltd. (SEP), London, and the extraordinary earnings associated with it. The sale will tentatively come into effect on 1st November.

It has been agreed to maintain silence regarding the value of the transaction.

curasan AG, thus, finalizes the concentration of the product portfolio in the biomaterials sector with the sale of the pharmaceutical drug Mitem®. The liquidity position of the company, which is very good anyway, will improve considerably as a result of this development.

About Speciality European Pharma Ltd:
Founded in April 2006, SEP is a privately owned speciality pharmaceutical company. Its mission is to become the leading urology-focused speciality pharmaceutical business in Europe. SEP owns worldwide rights to PLENAXIS®. SEP has distribution rights in a number of European countries for Haemopressin®/Variquel®, a product for the treatment of Bleeding Oesophageal Varices. In the UK and Ireland, SEP also has the distribution rights to Regurin® for the treatment of overactive bladder. The new once daily formulation, Regurin® XL, was launched in September 2009.
SEP has established its own commercial operations in the UK, Germany, France and Italy and will market its products in other regions and territories through relationships with expert partners.
To learn more about Speciality European Pharma, please visit www.specialityeuropeanpharma.com

# # #

Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.